ArticleScientific reports2025
The EZ-ALBI and PALBI scores contribute to the clinical application of ALBI in predicting postoperative recurrence of HCC.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Construction and validation of a prediction model for graft failure in pediatric liver transplant recipients based on the APRI-ALBI score: a retrospective study of 289 cases.Annals of medicine · 2026Article
- CRAFITY and PALBI Define a Machine Learning-Supported Prognostic Framework in Hepatocellular Carcinoma-Data from an Eastern European Cohort with Low Macrotrabecular-Massive Prevalence.Diseases (Basel, Switzerland) · 2026Article
- Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Prognostic value of easy Albumin-Bilirubin score in liver cirrhosis: a comparison with established scoring systems.European journal of gastroenterology & hepatology · 2026Article
- Integrated multi-dataset screening to predict prognosis and identify immunotherapy gene targets in hepatocellular carcinoma patients.Scientific reports · 2026Article
- NLR-PALBI Score and Its Grading: Predicting Overall Survival of Patients with Primary Liver Cancer Undergoing Transcatheter Arterial Chemoembolisation.Journal of hepatocellular carcinoma · 2026Article
- Future directions in prognostic modeling for dengue-induced severe hepatitis.World journal of hepatology · 2025Article
- Machine learning-driven prediction of intratumoral tertiary lymphoid structures in hepatocellular carcinoma using contrast-enhanced CT imaging and integrated clinical data.Frontiers in oncology · 2025Article
- Effect of Partial Splenic Embolization on Immune Environment and Hepatic Function in Cirrhosis Patients With Portal Hypertension.In vivo (Athens, Greece)Article
- Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This research intends to assess the variance between EZ-ALBI and PALBI in forecasting recurrence following the resection of hepatocellular carcinoma (HCC). A retrospective analysis was conducted using clinical data from 522 HCC patients across two medical institutions. The study analyzed albumin-bilirubin values (ALBI), along with the Easy albumin-bilirubin values (EZ-ALBI) and the Platelet-albumin-bilirubin values(PALBI), while assessing the clinical traits of patients across various grades. The analysis focused on the connections between ALBI, EZ-ALBI, and PALBI, as well as their variations in predicting the recurrence of HCC following surgical procedures. Notably, the clinical characteristics of patients exhibiting varying levels of PALBI differed from those categorized under ALBI and EZ-ALBI; however, the ALBI grade shared similar characteristics with the EZ-ALBI category. A strong correlation was found between ALBI and EZ-ALBI, with a coefficient of 0.862 (95% CI: 0.838-0.882, p < 0.01), whereas ALBI and PALBI yielded a coefficient of 0.760 (95% CI: 0.838-0.882, p < 0.01). The correlation coefficient between PALBI and EZ-ALBI was recorded at 0.571 (95% CI: 0.510-0.626, p < 0.01). There was a notable difference in survival outcomes among HCC patients classified with ALBI/EZ-ALBI/PALBI grade 1 compared to those with grade 2 or 3. Additionally, Cox regression analysis identified that maximum tumor diameter (MTD), microvascular invasion (MVI), pathological grade, as well as ALBI/EZ-ALBI/PALBI grades, among other factors, were tied to a decline in progression-free survival (PFS). The area under the curve (AUC) for the ALBI model at the 1, 2, and 3-year postoperative mark was 0.705, 0.652, and 0.694, respectively. In parallel, the AUC of the EZ-ALBI model during the same time intervals was 0.708, 0.659, and 0.694, respectively. For PALBI, the AUC values recorded at 1, 2, and 3 years following surgery were 0.748, 0.707, and 0.725, respectively. ALBI, EZ-ALBI, and PALBI served as predictive indicators for the recurrence of HCC in patients after surgery. Compared to ALBI, EZ-ALBI offers greater convenience in forecasting the prognosis of HCC patients, whereas PALBI demonstrates more accuracy than ALBI in predicting their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.